Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension

Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a devastating and fatal chronic lung disease. While current pharmacotherapies have improved patient quality of life, PAH drugs suffer from limitations in the form of short-term pharmacokinetics, instability, and poor organ specificity. Traditionally, nanotech...

Full description

Bibliographic Details
Main Authors: Victor Segura-Ibarra, Suhong Wu, Nida Hassan, Jose A. Moran-Guerrero, Mauro Ferrari, Ashrith Guha, Harry Karmouty-Quintana, Elvin Blanco
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-07-01
Series:Frontiers in Physiology
Subjects:
pulmonary arterial hypertension
chronic lung disease
nanomedicine
nanoparticles
drug delivery
Online Access:https://www.frontiersin.org/article/10.3389/fphys.2018.00890/full

Internet

https://www.frontiersin.org/article/10.3389/fphys.2018.00890/full

Similar Items